US stock · Healthcare sector · Medical Instruments & Supplies
A
Antares Pharma, Inc.
ATRS
NASDAQ5.59
USD
- -
(- -)
Market Closed
24.09P/E
- -Forward P/E
1.16P/E to S&P500
- -MMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
Short % of Float
- -
Short % of Shares Outs.
- -
% Held by Insiders
- -
% Held by Institutions
- -
Beta
1.15
PEG Ratio
- -
52w. high/low
- -/- -
Avg. Daily Volume
4.95M
Return %
Stock
S&P 500
1 year
36.01
(2.64)
3 years
96.14
46.00
5 years
114.18
68.59
Scale: |
High
Low
2.15
0.92
1.10
0.29
1.31
0.30
2.00
1.07
2.88
1.50
5.58
2.00
5.15
3.35
5.01
1.82
3.04
1.21
2.45
0.67
4.09
1.58
3.93
1.85
5.13
2.60
4.65
1.60
5.07
3.11
5.60
3.11
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.08
0.13
0.08
0.11
0.15
0.17
0.20
0.16
0.20
0.31
0.34
0.35
0.39
0.61
0.90
1.11
1.08
Earnings per share
(0.16)
(0.14)
(0.19)
(0.14)
(0.07)
(0.05)
(0.10)
(0.16)
(0.27)
(0.14)
(0.16)
(0.11)
(0.04)
(0.01)
0.34
0.28
0.24
FCF per share
(0.12)
(0.09)
(0.18)
(0.07)
(0.08)
(0.03)
(0.13)
(0.14)
(0.25)
(0.24)
(0.13)
(0.16)
(0.11)
(0.06)
0.04
0.18
0.14
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.00
0.00
0.02
0.00
0.00
0.01
0.03
0.02
0.04
0.05
0.03
0.01
0.01
0.01
0.09
0.04
0.03
Book Value per sh.
0.10
0.29
0.11
0.12
0.08
0.32
0.79
0.56
0.32
0.46
0.29
0.21
0.24
0.27
0.72
1.06
0.92
Comm.Shares outs.
52
60
67
73
83
97
110
127
131
147
155
156
163
203
166
166
170
Avg. annual P/E ratio
(8.3)
(9.6)
(3.9)
(5.6)
(20.6)
(44.9)
(33.7)
(25.0)
(11.0)
(14.9)
(8.2)
(24.6)
(69.5)
(339.0)
9.0
14.3
24.1
P/E to S&P500
(0.5)
(0.6)
(0.2)
(0.1)
(1.0)
(2.8)
(2.3)
(1.5)
(0.6)
(0.7)
(0.4)
(1.0)
(2.8)
(14.0)
0.2
0.5
1.2
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
4
8
6
8
13
16
23
21
27
46
52
55
64
124
150
184
183
Operating margin
(193.9)%
(110.0)%
(215.5)%
(116.6)%
(47.0)%
(27.0)%
(50.7)%
(101.1)%
(132.5)%
(44.8)%
(46.2)%
(30.2)%
(6.5)%
0.8%
9.1%
35.8%
29.7%
Depreciation (m)
0
3
0
0
0
0
0
1
1
2
2
2
3
3
3
4
4
Net profit (m)
(8)
(9)
(13)
(10)
(6)
(4)
(11)
(21)
(35)
(21)
(24)
(17)
(7)
(2)
56
46
42
Income tax rate
- -
- -
- -
- -
- -
- -
- -
1.4%
(0.1)%
(0.9)%
(0.4)%
- -
- -
- -
(466.5)%
25.7%
14.6%
Net profit margin
(189.8)%
(109.2)%
(224.2)%
(123.8)%
(47.5)%
(26.7)%
(50.6)%
(99.5)%
(132.6)%
(45.2)%
(46.6)%
(30.7)%
(10.3)%
(1.6)%
37.6%
25.2%
21.9%
Working capital (m)
6
22
8
8
6
26
70
56
29
49
25
40
44
76
63
103
116
Long-term debt (m)
- -
5
2
- -
- -
- -
- -
- -
- -
- -
- -
25
22
40
25
20
23
Equity (m)
5
17
7
9
7
31
87
71
41
67
45
34
39
55
119
176
176
ROIC
- -
- -
- -
- -
- -
- -
(13.0)%
(28.3)%
(78.9)%
(30.5)%
(52.4)%
(26.1)%
(6.3)%
1.5%
52.0%
23.3%
24.3%
Return on capital
(70.2)%
(28.4)%
(58.6)%
(50.4)%
(40.2)%
(10.5)%
(12.0)%
(23.4)%
(51.1)%
(24.2)%
(36.5)%
(20.6)%
(4.3)%
1.1%
6.4%
24.2%
22.2%
Return on equity
(159.4)%
(49.0)%
(175.2)%
(116.3)%
(91.9)%
(14.1)%
(13.2)%
(29.0)%
(85.3)%
(30.8)%
(53.8)%
(49.9)%
(16.7)%
(3.7)%
47.2%
26.3%
24.2%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
10 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 80
Total assets
$ 256
Long-term debt
$ 23
Cash and equiv.
$ 62
Goodwill
$ 1
Retained earnings
$ (179)
Common stock
170
Enterprise Value
$ - -
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
46
53
67
Receivables
43
50
83
Inventory
16
18
12
Other
3
35
43
Current assets
108
127
162
Acc. Payable
13
16
17
Debt due
1
17
4
Other
18
30
38
Current liabilities
32
63
59
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
22.98%
38.81%
29.57%
Cash flow
347.46%
35.42%
26.16%
Earnings
(17.64)%
(755.06)%
(324.89)%
Dividends
- -
- -
- -
Book value
47.55%
55.53%
18.49%
Insider Trading
Type
Shares
Date
Roche Robert P Jr
Return
48,542
05/24/22
Roche Robert P Jr
Return
48,542
05/24/22
Gueth Anton
Return
48,542
05/24/22
Gueth Anton
Return
48,542
05/24/22
Richardson Peter C
Return
69,037
05/24/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
33
32
40
44
150
2021
42
45
48
49
184
2022
42
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.01)
0.01
0.03
0.31
0.34
2021
0.02
0.04
0.03
0.20
0.29
2022
(0.01)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. Robert Apple
Full-time employees:
201
City:
Ewing
Address:
SUITE 300, 100 PRINCETON SOUTH
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Recent News
· 13 Apr, 2022 · The Wall Street Journal